Grifois, S.A.

GRFSStock

$7.33−23.82%52W

Market Cap$6.21B

P/E13.49x

Div yield2.09%

Beta0.68

Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-28.09%

Price vs S&P 500 (4W)-0.46%

VGM Score44.24

Market Capitalization$6.21B

P/E Ratio (Annual)13.49x

Indicated Dividend Yield (Annual)2.09%

Analyst Recommendations

Apr 2026

May 2026

Jun 2026

Jul 2026

3.81

About

Grifols is a global specialty plasma therapeutics company that develops, manufactures, and distributes protein-based medicines for immunological deficiencies, hemophilia, and other chronic and life-threatening conditions. The company's portfolio serves both diagnostic and therapeutic applications across rare and inherited diseases with significant unmet medical needs. Grifols generates the majority of its revenue from the United States market.